Clinical Trial Update: SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating adding a SGLT2 inhibitor to lifestyle interventions to assess risk of complications in subtypes of patients with prediabetes; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prediabetes
• Renal Failure
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitor

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Type2diabetes, PreDiabetes | Phase 4 | Status: RECRUITING